This invention relates to novel cyclopentyl- and cycloheptylpyrazole derivatives of the formula I
wherein A and R
1
to R
4
are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. The invention relates also to compositions including these compounds and methods of using the compounds.
[EN] CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS<br/>[FR] CYCLOPENTYL- ET CYCLOHEPTYLPYRAZOLES UTILISÉS COMME MODULATEURS DU RÉCEPTEUR X DES FARNÉSOÏDES (FXR)
申请人:HOFFMANN LA ROCHE
公开号:WO2011117163A1
公开(公告)日:2011-09-29
This invention relates to novel cyclopentyl- and cycloheptylpyrazole derivatives of the formula (I) wherein A and R1 to R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof, to compositions including these compounds and methods of using the compounds.
INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES
申请人:Benson Gregory Martin
公开号:US20100076027A1
公开(公告)日:2010-03-25
This invention relates to novel indazole or 4,5,6,7-tetrahydro-indazole derivatives of formula I
wherein R
1
to R
8
are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be used as medicaments.
Inhibitors of the Human Aldosterone Sythase CYP11B2
申请人:Hartmann Rolf W.
公开号:US20110112067A1
公开(公告)日:2011-05-12
The invention provides compounds of the general formula (I)
which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and/or disorders or diseases that are mediated by 11β-hydroxylase (CYP11B1) with these compounds.
6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2
申请人:Hartmann Rolf W.
公开号:US20110118241A1
公开(公告)日:2011-05-19
The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 β-hydroxylase (CYP11 B1).